Arcus Biosciences Inc
NYSE:RCUS

  • LAST PRICE
    15.8300
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    15.0000/ 5
  • Ask / Lots
    16.1100/ 1
  • Open / Previous Close
    16.3200 / 15.8300
  • Day Range
    15.5300
    16.4200
  • 52 Week Range
    12.9500
    25.4700
  • Volume
    921,978

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

      Show headlines and story abstract

    • 9 hours ago by Business Wire
      Companies Mentioned: RCUS

      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 3,500 shares of the Company's common stock at an exercise price per share of $16.41, which was the closing price on June 24, 2024, and restricted stock units to acquire a total of 1,750 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.

    • 9 hours ago by Dow Jones
      Companies Mentioned: RCUS
      HAYWARD, Calif.--(BUSINESS WIRE)--June 25, 2024--
      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 3,500 shares of the Company's common stock at an exercise price per share of $16.41, which was the closing price on June 24, 2024, and restricted stock units to acquire a total of 1,750 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.

  • Jun 24, 2024

  • Jun 11, 2024

      Show headlines and story abstract

    • 4:35PM ET on Tuesday Jun 11, 2024 by Business Wire
      Companies Mentioned: RCUS

      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted six new employees options to purchase a total of 36,100 shares of the Company's common stock at an exercise price per share of $16.09, which was the closing price on June 10, 2024, and restricted stock units to acquire a total of 18,050 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.

Peers Headlines